Enlivex Ltd. ENLV
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Enlivex Ltd. (ENLV) is a healthcare company listed in the US with a market value of about $2M.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.0, a 5-year average ROIC of -36%.
About Enlivex
Enlivex is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. It was profitable in 1 of the last 10 years in our data.
Score: 1.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | $1.2B | -$15M | -$29M | -$31M | -$14M | -$12M | -$9M | -$4M | -$3M | -$16M |
| Free cash flow | -$10M | -$13M | -$24M | -$32M | -$19M | -$12M | -$7M | -$4M | -$2M | -$16M |
| EPS (diluted) | $806.48 | $-9.80 | $-18.97 | $-20.27 | $-9.44 | $-7.72 | $-6.13 | $-2.77 | $-1.63 | $-10.46 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -0.6% | -52.0% | -74.6% | -33.0% | -17.9% | -21.8% | -60.4% | -54.5% | -20.2% | -446.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Enlivex’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Does Enlivex pay a dividend?
Not currently.
Is Enlivex a good stock to buy?
We do not give buy or sell advice. Enlivex scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.